303 related articles for article (PubMed ID: 29644440)
1. A liquid biopsy in primary lung cancer.
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
Surg Today; 2019 Jan; 49(1):1-14. PubMed ID: 29644440
[TBL] [Abstract][Full Text] [Related]
2. Tumor-educated platelet as liquid biopsy in lung cancer patients.
Liu L; Lin F; Ma X; Chen Z; Yu J
Crit Rev Oncol Hematol; 2020 Feb; 146():102863. PubMed ID: 31935617
[TBL] [Abstract][Full Text] [Related]
3. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
4. Are liquid biopsies a surrogate for tissue EGFR testing?
Goldman JW; Noor ZS; Remon J; Besse B; Rosenfeld N
Ann Oncol; 2018 Jan; 29(suppl_1):i38-i46. PubMed ID: 29462257
[TBL] [Abstract][Full Text] [Related]
5. Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.
Lin CC; Huang WL; Wei F; Su WC; Wong DT
Expert Rev Mol Diagn; 2015; 15(11):1427-40. PubMed ID: 26420338
[TBL] [Abstract][Full Text] [Related]
6. [Relevance of circulating tumor DNA in lung cancer: A case report].
Amrane K; Le Gac G; Descourt R; Quere G
Rev Mal Respir; 2016 Nov; 33(9):804-807. PubMed ID: 27132215
[TBL] [Abstract][Full Text] [Related]
7. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.
Guibert N; Tsukada H; Hwang DH; Chambers E; Cibas ES; Bale T; Supplee J; Ulrich B; Sholl LM; Paweletz CP; Oxnard GR
Lung Cancer; 2018 Aug; 122():72-75. PubMed ID: 30032849
[TBL] [Abstract][Full Text] [Related]
9. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
10. Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer.
Kim E; Feldman R; Wistuba II
Clin Lung Cancer; 2018 Mar; 19(2):105-114. PubMed ID: 28935493
[TBL] [Abstract][Full Text] [Related]
11. Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy: a case report.
Sorber L; Zwaenepoel K; Wouters A; Janssens A; Hiddinga B; Van Meerbeeck J; Lardon F; Pauwels P; Rolfo C
J Clin Pathol; 2018 Aug; 71(8):754-756. PubMed ID: 29853531
[No Abstract] [Full Text] [Related]
12. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
13. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
[TBL] [Abstract][Full Text] [Related]
14. Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?
Marcq M; Vallée A; Bizieux A; Denis MG
J Thorac Oncol; 2014 Jul; 9(7):e49-e50. PubMed ID: 24926553
[No Abstract] [Full Text] [Related]
15. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K
Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
17. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR.
Kuang Y; O'Connell A; Sacher AG; Feeney N; Alden RS; Oxnard GR; Paweletz CP
Methods Mol Biol; 2018; 1768():193-207. PubMed ID: 29717445
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
Zhang C; Wei B; Li P; Yang K; Wang Z; Ma J; Guo Y
PLoS One; 2017; 12(3):e0173524. PubMed ID: 28333951
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor T790M testing in progressed lung cancer: A review of sensitive methods for analysis of tissue and liquid biopsy samples.
Chougule A; Basak S
Indian J Cancer; 2017 Dec; 54(Supplement):S45-S54. PubMed ID: 29292708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
